KLRC1 and chronic myelogenous leukemia, BCR-ABL1 positive: Altogether, the increased expression of NKG2A in the CD56bright subset could be interpreted as an increased killing capacity against target cells with lower expression of HLA-E, such as cancerous cells or CML cells [11].